{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:59:58Z","timestamp":1783702798541,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL134952"],"award-info":[{"award-number":["R01HL134952"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL147978"],"award-info":[{"award-number":["R01HL147978"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01187-4","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T10:42:40Z","timestamp":1732617760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["RSK1 dependency in FLT3-ITD acute myeloid leukemia"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3240-8989","authenticated-orcid":false,"given":"Tim","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo B. A.","family":"Laranjeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Letson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LaYow","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarthi","family":"Jayanthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit","family":"Los","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra E.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4669-8814","authenticated-orcid":false,"given":"Grant A.","family":"Challen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8564-5400","authenticated-orcid":false,"given":"Stephen T.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"1187_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6:e441.","journal-title":"Blood Cancer J"},{"key":"1187_CR2","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","author":"Consortium APG.","year":"2017","unstructured":"Consortium APG. AACR project GENIE: powering precision medicine through an international consortium. Cancer Discov. 2017;7:818\u201331.","journal-title":"Cancer Discov"},{"key":"1187_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.612880","volume":"10","author":"VE Kennedy","year":"2020","unstructured":"Kennedy VE, Smith CC. FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies. Front Oncol. 2020;10:612880.","journal-title":"Front Oncol"},{"key":"1187_CR4","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374.","journal-title":"N Engl J Med"},{"key":"1187_CR5","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562:526\u201331.","journal-title":"Nature"},{"key":"1187_CR6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/cas.14274","volume":"111","author":"H Kiyoi","year":"2020","unstructured":"Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020;111:312\u201322.","journal-title":"Cancer Sci"},{"key":"1187_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299\u2013312.","journal-title":"Leukemia"},{"key":"1187_CR8","first-page":"108","volume":"4","author":"T Kong","year":"2023","unstructured":"Kong T, Laranjeira ABA, Yang K, Fisher DAC, Yu L, Poittevin De La Fregonniere L, et al. DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression. Nat Cancer. 2023;4:108\u201327.","journal-title":"Nat Cancer"},{"key":"1187_CR9","doi-asserted-by":"crossref","unstructured":"Watanabe D, Nogami A, Okada K, Akiyama H, Umezawa Y, Miura O. FLT3-ITD activates RSK1 to enhance proliferation and survival of AML cells by activating mTORC1 and eIF4B cooperatively with PIM or PI3K and by inhibiting Bad and BIM. Cancers. 2019;11:1827.","DOI":"10.3390\/cancers11121827"},{"key":"1187_CR10","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.18632\/oncotarget.27630","volume":"11","author":"HD Chae","year":"2020","unstructured":"Chae HD, Dutta R, Tiu B, Hoff FW, Accordi B, Serafin V, et al. RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit. Oncotarget. 2020;11:2387\u2013403.","journal-title":"Oncotarget"},{"key":"1187_CR11","doi-asserted-by":"crossref","unstructured":"Dunn SE, Jayanthan A, Huynh M-M, Flahive E, Pambid MR, Dorr A, et al. Abstract P3-10-10: PMD-026, a first-in-class oral p90 ribosomal S6 kinase (RSK) inhibitor for triple negative breast cancer (TNBC). Cancer Res. 2020;80:P3\u201310.","DOI":"10.1158\/1538-7445.SABCS19-P3-10-10"},{"key":"1187_CR12","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1158\/1538-7445.AM2021-1038","volume":"81","author":"A Jayanthan","year":"2021","unstructured":"Jayanthan A, Huynh M-M, Lee J, Los G, Yue L, Pambid MR, et al. Abstract 1038: PMD-026, a first in class oral RSK inhibitor, demonstrates synergy when combined with standard of care in breast cancer tumor models. Cancer Res. 2021;81:1038.","journal-title":"Cancer Res"},{"key":"1187_CR13","doi-asserted-by":"crossref","unstructured":"Kong T, Laranjeira ABA, Letson CT, Yu L, Lin S, Fowles JS, et al. RSK1 is an exploitable dependency in myeloid malignancies. Nat Commun. 2024.","DOI":"10.1182\/blood-2023-182320"},{"key":"1187_CR14","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40:850\u201364.e9.","journal-title":"Cancer Cell"},{"key":"1187_CR15","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1182\/bloodadvances.2022007952","volume":"6","author":"DR Buelow","year":"2022","unstructured":"Buelow DR, Bhatnagar B, Orwick SJ, Jeon JY, Eisenmann ED, Stromatt JC, et al. BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors. Blood Adv. 2022;6:5049\u201360.","journal-title":"Blood Adv"},{"key":"1187_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.stemcr.2020.02.011","volume":"14","author":"EL Ostrander","year":"2020","unstructured":"Ostrander EL, Kramer AC, Mallaney C, Celik H, Koh WK, Fairchild J, et al. Divergent effects of Dnmt3a and Tet2 mutations on hematopoietic progenitor cell fitness. Stem Cell Rep. 2020;14:551\u201360.","journal-title":"Stem Cell Rep"},{"key":"1187_CR17","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/nrd.2016.184","volume":"15","author":"RK Harrison","year":"2016","unstructured":"Harrison RK. Phase II and phase III failures: 2013\u20132015. Nat Rev Drug Discov. 2016;15:817\u20138.","journal-title":"Nat Rev Drug Discov"},{"key":"1187_CR18","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N. Engl J Med. 2019;381:1728\u201340.","journal-title":"N. Engl J Med"},{"key":"1187_CR19","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.2217\/fon.14.105","volume":"10","author":"M Levis","year":"2014","unstructured":"Levis M. Quizartinib for the treatment of FLT3\/ITD acute myeloid leukemia. Future Oncol. 2014;10:1571\u20139.","journal-title":"Future Oncol"},{"key":"1187_CR20","doi-asserted-by":"crossref","unstructured":"Wang JS, Beeram M, Chalasani P, Mina L, Shatsky RA, Hurvitz S, et al. High levels of RSK2 in breast cancer patients is associated with longer PFS in patients treated with PMD-026, a first in class RSK inhibitor. SABCS. Cancer Res. 2023;83:P4-01-16. https:\/\/aacrjournals.org\/cancerres\/article\/83\/5_Supplement\/P4-01-16\/718165\/Abstract-P4-01-16-High-levels-of-RSK2-in-breast.","DOI":"10.1158\/1538-7445.SABCS22-P4-01-16"},{"key":"1187_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"1187_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139\u201340.","journal-title":"Bioinformatics"},{"key":"1187_CR23","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.","journal-title":"Nucleic Acids Res"},{"key":"1187_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"1187_CR25","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1187_CR26","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/ng.3984","volume":"49","author":"RM Meyers","year":"2017","unstructured":"Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017;49:1779\u201384.","journal-title":"Nat Genet"},{"key":"1187_CR27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01187-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01187-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01187-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T11:03:59Z","timestamp":1732619039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01187-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1187"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01187-4","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"3 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"STO has served as a consultant for Kartos Therapeutics, CTI BioPharma, Celgene\/Bristol Myers Squibb, Disc Medicine, Protagonist, Blueprint Medicines, Cogent, PharmaEssentia, Constellation, Geron, Abbvie, Sierra Oncology, and Incyte. MH, GL, and SED, are employees of Phoenix Molecular Designs. GAC has received funding for consulting and\/or sponsored research from Incyte, Ajax Therapeutics, and Renagade Therapeutics. All other authors disclose no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"207"}}